The Food and Drug Administration (FDA) also approved APR-246 combined with azacitidine for the treatment of Li-Fraumeni syndrome complicated with MDS in January 2020. A recent study showed that APR-246 and azacitidine play a synergistic role in TP53-mutated MDS/AML, which can restore the transcriptional activation function of mutant TP53 and induce apoptosis of human tumor cells (14), and preclinical trials are currently underway. This evidence concerns the gene TP53 and neoplasm.